Three-Year Follow-Up Data Showed Patients Achieved Four-Fold Progression-Free Survival Benefit with Single Agent Imbruvica®? (ibrutinib) vs Temsirolimus at First Relapse in Mantle Cell Lymphoma
To view full article click here
To view full article click here